⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RGNX News
REGENXBIO Inc.
RARE Drug Development Symposium Marks 10th Anniversary with Dedicated Pitch Sessions and The Theme and Call to Action to Align Advocates, Science and Industry
prnewswire.com
BIIB
REGN
GILD
BTE
BROS
BFLY
BCTX
BCRX
BTAI
ALRS
CAPR
CRIS
CYCN
EXAS
FATE
GNTX
HRMY
INCY
IONS
KODK
LAKE
LULU
MRNA
NBIX
NTRA
OCGN
ORGN
PGEN
PLRX
RARE
RGNX
RXRX
SAVA
SGMO
SNOW
SRPT
STEM
TGTX
TLSA
TXG
VRTX
ZETA
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm
prnewswire.com
RGNX
Form 8-K
sec.gov
RGNX
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
prnewswire.com
RGNX
REGENXBIO Announces Proposed Public Offering of Common Stock
prnewswire.com
RGNX
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm
globenewswire.com
RGNX
Lifshitz Law PLLC Announces Investigations of Corcept Therapeutics, Inc. (NASDAQ: CORT), Gartner, Inc. (NYSE: IT), REGENXBIO Inc. (NASDAQ: RGNX), and Graphic Packaging Holding Company (NYSE: GPK)
accessnewswire.com
CORT
IT
RGNX
GPK
Form 8-K
sec.gov
RGNX
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
prnewswire.com
RGNX
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
prnewswire.com
RGNX